Shriya Syal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shriya Syal has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Crystal L. Mackall
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
26 shared publications - David Bernard Miklos
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
26 shared publications - Lori Muffly
Stanford University, Stanford, California, United States
26 shared publications - Matthew J. Frank
Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA
26 shared publications - Agnes Reschke
Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California
25 shared publications - Alexandria Mary Jensen
Stanford University, Stanford, California, United States
25 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 13 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 13 shows ROC curves for the two cytokine signature at D14 and D21
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 13 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 13 shows ROC curves for the two cytokine signature at D14 and D21
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 1 shows individual lab values over time for grade 2+ IECHS
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 1 shows individual lab values over time for grade 2+ IECHS
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 7 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr2+ CRS.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 7 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr2+ CRS.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 5 shows cellular composition of apheresis material (A) and infused products (B) by IECHS severity.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 5 shows cellular composition of apheresis material (A) and infused products (B) by IECHS severity.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 8 shows the individual laboratory and CAR T values for the patient with severe IECHS who underwent daily cytokine profiling.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 8 shows the individual laboratory and CAR T values for the patient with severe IECHS who underwent daily cytokine profiling.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Baseline characteristics of the cohort by disease.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Baseline characteristics of the cohort by disease.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 3 shows lab values over time in grade 2+ vs no IECHS by underlying malignancy
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 3 shows lab values over time in grade 2+ vs no IECHS by underlying malignancy
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr1 IEC-HS.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr1 IEC-HS.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 6 shows T cell phenotypes in the manufactured products of CD4 (A) and CD8 (B) T cells
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 6 shows T cell phenotypes in the manufactured products of CD4 (A) and CD8 (B) T cells